Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Webinars

Thu
Feb
09
1:00 PM
US Eastern

Sponsored by Illumina

Comprehensive Genomic Profiling in the Community Setting: Perspective from a Pathologist and an Oncologist

Comprehensive Genomic Profiling (CGP) is a next-generation sequencing technology that identifies genomic alterations across hundreds of genes using a single assay. The utilization of CGP in clinical labs is a powerful approach to personalize cancer treatment options. Implementing CGP in-house offers the opportunity to reduce turnaround time and empower clinicians to make informed decisions for patient management.

In this webinar, Dr. Carlo Bifulco and Dr. Rachel Sanborn will provide insights into the benefits of in-house CGP testing at Providence Cancer Institute and how this approach can foster stronger multidisciplinary collaboration and patient management, with the potential to improve patient care. The speakers will highlight the impact of in-house CGP in patient care via case study examples. The potential future opportunities of CGP will also be highlighted.

Sponsored by

Tue
Feb
21
1:00 PM
US Eastern

Advanced Comprehensive Genomic Panels for Myeloid Neoplasms: Implementation and Practice of Anchored Multiplex PCR (AMP) Technology at GenPath Oncology

Multiplex NGS panels are emerging as the standard-of-care solution for genomic profiling in myeloid neoplasms including myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia. Wojciech Swat, the medical director of the cancer genomics and molecular pathology divisions at GenPath, uses rapid-throughput NGS research panels leveraging anchored multiplex PCR (AMP) technology to assist hematopathology colleagues in their morphologic evaluations of myeloid malignancy in bone marrow biopsies. Such panels help in diagnosis, risk stratification, prognosis, and longitudinal tracking of malignant clones. Genomic profiling by NGS can significantly streamline laboratory workflows, provide comprehensive assessments with vastly reduced TATs, and improve analytic sensitivity and specificity in comparison with traditional testing methodologies such as PCR/fragment analysis and Sanger sequencing.

During this presentation, Swat will talk about his experience at GenPath laboratories with the rapid-throughput, multiple-panel Archer VariantPlex Myeloid and FusionPlex Myeloid Research Use Only (RUO) Assays, which are capable of delivering results in two days, can track the MRD of specific clones, and can detect the emergence of subclones with variant allele frequencies as low as 0.1 percent.

Tue
Feb
28
11:00 AM
US Eastern

Sponsored by SeqOne

A Clinically Validated and Easy-to-Implement HRD Scoring Solution Using a Targeted Panel and Shallow Whole-Genome Sequencing

The PAOLA-1/ENGOT-ov25 Phase III trial is a first-line-treatment study for advanced ovarian cancer which showed that the maximum benefit of the PARP inhibitor olaparib plus bevacizumab maintenance is observed in patients with homologous recombination-deficient (HRD) tumors.

In this webinar, Pascal Pujol of the University of Montpellier will describe a retrospective clinical evaluation — using PAOLA-1 data — of an HRD scoring solution based on low-coverage and cost-effective whole-genome sequencing (WGS). The SeqOne HRD solution combines genomic instability and CCNE1 gene amplification features extracted from WGS, as well as pathogenic mutations in BRCA 1/2 genes. Pujol will describe dilution experiments that determine the lower limit for sequencing coverage and tumoral content. The clinical evaluation of 368 patients from the PAOLA-1 trial included progression-free survival (PFS) data and comparisons with the MyChoice CDx test. The evaluation found the SeqOne HRD solution to be cost-effective and efficient with a low tumoral content while being flexible by accommodating different lab configurations.

Pujol will be joined by Michael Blum, director of research and development at SeqOne, who will describe the SeqOne approach to HRD testing.

Sponsored by

SeqOne Logo.png
Tue
Feb
28
1:00 PM
US Eastern

Sponsored by Invivoscribe

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

Chronic lymphocytic leukemia (CLL) is a slow-developing, incurable leukemia. The availability of multiple diagnostic tools and platforms enables the identification of the disease and disease time course as well as better-informed treatment decisions. With the advent of advanced multiparameter flow cytometric (MFC) assays, CLL-specific molecular biomarkers may provide predictive and prognostic information, permitting population stratification into subsets defined by disease progression, response to therapy, etc.

In this session, Joseph Annunziata of Kindred Healthcare will discuss diagnostic and measurable residual disease (MRD) monitoring approaches to CLL and the benefits of predictive and prognostic assessments using multimodality peripheral blood analyses. Moreover, this talk will include an emphasis on the role of MRD in CLL drug development.

During this webinar, Annunziata will:

  1. Compare various diagnostic approaches for CLL.
  2. Highlight the predictive and prognostic benefits of molecular testing for CLL.
  3. Assess MRD methods for long-term monitoring in CLL patients.
  4. Explore the advanced role of MFC-based CLL MRD in drug research and development.

Sponsored by

Tue
Mar
07
11:00 AM
US Eastern

Sponsored by Qiagen

Comprehensive Molecular Tumor Analysis: Integrating RNAseq and Tumor Immune Microenvironment for Targeted Therapy

Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an additional level of insight that cannot be provided by genomic data alone. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Comprehensive molecular tumor analysis (CMTA) is an NGS-based tumor diagnostic test developed by Alacris Theranostics. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq) and is deployed as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. Designed to serve all cancer patients, CMTA is a tumor-agnostic test that displays a unique molecular view of each sample and is particularly well-suited to refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, Alacris Theranostics will discuss the benefits of comprehensive tumor profiling in clinical settings and present the strategy implemented in their bioinformatics pipeline to identify cancer-relevant somatic events. In addition, the diagnostic company will share how they use QIAGEN Clinical Insight (QCI) Interpret to annotate variants and identify potential therapeutic entry points.

Sponsored by

field_file_image_alt_text_value